- Trial phase
- Approved
- Time to market
- Already FDA-approved (October 8, 2026) and launching commercially in the US. Teva's inpatient free trial site indicates the product is preparing for commercial availability in the coming weeks. EMA review in Europe is ongoing with no decision date set.
- Why 4/10
- WELTRUZA was FDA-approved on October 8, 2026, so the binary approval catalyst has already passed. There is no upcoming PDUFA or pivotal readout for this drug in the next ~12 months (the EMA MAA is under review but undated). As an approved, launching product at a large diversified pharma company, the impactScore is 4.
WELTRUZA is already FDA-approved and launching; the next potential catalyst is an EMA decision on the MAA accepted in May 2026, though no specific date is set. Watch for early commercial uptake metrics in Teva's quarterly earnings and any formulary access wins, as these will signal whether the $1.5B-$2B franchise peak-sales target is credible.
Price Chart
Executive Summary
WELTRUZA (olanzapine) is a once-monthly subcutaneous long-acting injectable for schizophrenia, approved by the FDA on October 8, 2026. It is the first and only olanzapine LAI that requires no loading dose, no oral supplementation, and no mandatory post-injection observation, addressing a key safety/compliance gap versus the older Zyprexa Relprevv. Developed by Teva Pharmaceutical Industries (NYSE: TEVA) using Medincell's controlled-release technology, the drug is based on positive Phase 3 SOLARIS trial data. Teva has set a WAC price of $3,950 and targets a combined $1.5B-$2B peak sales for its Uzedy/Weltruza schizophrenia franchise. The binary FDA approval catalyst has passed; the next potential catalyst is an EMA decision (MAA accepted May 2026, review ongoing).
How It Works
WELTRUZA is a long-acting injectable form of olanzapine, an atypical antipsychotic that works by blocking several brain receptors (dopamine and serotonin) to reduce hallucinations, delusions, and disorganized thinking in schizophrenia. The drug is formulated as a slow-release suspension injected under the skin once a month, using Medincell's proprietary technology to release the medication steadily over time.
Trial Status
FDA approval was based on the Phase 3 SOLARIS trial (NCT05693935), a multinational, randomized, double-blind, placebo-controlled study of 675 adults aged 18-64 with schizophrenia. All three doses of WELTRUZA were similarly tolerated; common adverse events included increased weight, somnolence, headache, constipation, and injection site reactions. Weight gain and metabolic changes were consistent with oral olanzapine's known safety profile.
The Two-Sided Case
Upcoming Catalysts
- EMA decision on Marketing Authorization Application (MAA accepted May 2026, review ongoing, no specific date)
- First full quarter of US commercial sales data (likely Teva Q4 2026 earnings in early 2027)
- Formulary access and reimbursement decisions by major US payers
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Teva Pharmaceutical Industries Ltd PRESS-RELEASE TEVA ·Originating report